New hope for painful skin condition: drug trial targets chinese patients

NCT ID NCT07489573

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study tests a drug called secukinumab in Chinese adults with moderate to severe hidradenitis suppurativa, a painful skin condition that causes boils and tunnels under the skin. The goal is to see if the drug reduces skin lesions and prevents flare-ups over 16 weeks. About 36 participants will receive the drug every two or four weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA (HS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hidradenitis suppurativa Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIDRADENITIS SUPPURATIVA (HS)

Contacts and locations

Locations

Novartis Investigative Site
RECRUITING

Hangzhou, Zhejiang, 310006, China
Novartis Investigative Site
RECRUITING

Ningbo, Zhejiang, 315016, China
Novartis Investigative Site
RECRUITING

Wenzhou, Zhejiang, 325000, China
Novartis Investigative Site
RECRUITING

Beijing, 100191, China
Novartis Investigative Site
RECRUITING

Beijing, 100730, China
Novartis Investigative Site
RECRUITING

Shanghai, 200040, China
Novartis Investigative Site
RECRUITING

Tianjin, 300052, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.